Protasov D A, Zel'dovich D R, Kuz'mina L P, Manikhas G M
Municipal Oncological Dispensary, St. Petersburg.
Vopr Onkol. 1998;44(6):718-21.
The investigation was concerned with clinical application of cardioxane (dexrazoxan, ICRF-187) which is intended to counteract the cardiotoxic effect of anthracycline drugs. It was tested in 24 courses of combination chemotherapy (CAP) in 48 cases of extended ovarian tumor. The "threshold" total dose of doxorubin (500 mg/m2) which caused persistent cardiomyopathy in such patients as well as cases of relapse was practically never reached due to the absence of therapeutic effect. The total dose of doxorubicin of 120 mg/m2 raised the likelihood of acute cardiac intoxication. With prophylactic administration of cardioxane, clinical signs of acute cardiointoxication were slight; irreversible intoxication was recorded in 0.8%. The drug improved tolerance; it neither increased the overall toxicity of combination chemotherapy nor affected the results.
本研究关注卡地阿佐（右丙亚胺，ICRF-187）的临床应用，其旨在对抗蒽环类药物的心脏毒性作用。对48例晚期卵巢肿瘤患者进行了24个疗程的联合化疗（CAP）试验。由于缺乏治疗效果，实际上从未达到导致此类患者持续性心肌病以及复发病例的阿霉素“阈值”总剂量（500mg/m²）。阿霉素总剂量120mg/m²增加了急性心脏中毒的可能性。预防性给予卡地阿佐时，急性心脏中毒的临床症状轻微；不可逆中毒发生率为0.8%。该药物提高了耐受性；既未增加联合化疗的总体毒性，也未影响治疗结果。
